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Introduction
A phase 3 trial (TENDER) demonstrated the efficacy of the
interleukin-6 receptor inhibitor TCZ in pts with sjia [1,2].
Objectives
To investigate progression of radiographic joint damage
in pts with sjia treated with TCZ for up to 2 years in
TENDER.
Methods
112 pts 2-17 yrs old with active, refractory sjia of ≥6
months’ duration and inadequate response to previous
non-steroidal anti-inflammatory drugs and oral corticos-
teroids were enrolled in TENDER. Pts were randomised
2:1 to receive TCZ according to body weight (12 mg/kg
<30 kg or 8 mg/kg ≥30 kg) or placebo IV every 2 wks for
12 wks. Pts then received open-label TCZ in the ongoing
long-term extension. Radiographic progression was calcu-
lated as change in adapted Sharp/van der Heijde score
(ash) score and/or Poznanski score, assessed on hand and
wrist radiographs, from baseline to wks 52 and 104. Radio-
graphic progression was indicated by a positive ash score
change or negative Poznanski score change. Clinical
efficacy endpoints included American College of Rheuma-
tology (ACR) Paediatric (Pedi) 70/90 responses.
Results
Baseline and ≥1 postbaseline ash and Poznanski scores
were available for 47 and 33 pts, respectively (reasons for
missing x-rays: early withdrawal, no consent, unreadable
x-rays). Baseline characteristics for pts with radiographic
data were similar to the whole TCZ population [1]. Pts
with assessable ash/Poznanski scores had 5.2/4.8-yr dis-
ease duration, 21.3/19.2 active joints, 20.0/18.2 joints
with limitation of movement and erythrocyte sedimenta-
tion rates of 53.9/59.2 mm/h. At wks 52 and 104, 20 and
19 pts, respectively, had ash progression, and 8 and 6 pts,
respectively, had Poznanski score progression. Median
change in ash score from baseline to wks 52 and 104
were 0 and 0.5, respectively (Table). Median change in
Poznanski score from baseline to wks 52 and 104 were
0.3 and 0.17, respectively (Table 1).
Conclusion
Though changes in radiographic scores over time were seen
in many pts, on average, pts with sjia did not experience
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Table 1
Wk 52 Wk 104
Ash score (n = 47), median (IQR) 0.00 (-8.70: 4.00) 0.50 (-7.50: 12.00)
Poznanski score (n = 33), median
(IQR)
0.30 (-0.02: 1.03) 0.17 (0.01: 1.04)
ACR Pedi 70 (n = 112), n/N (%) 92/106 (86.8) 57/65 (87.7)
ACR Pedi 90 (n = 112), n/N (%) 67/106 (63.2) 46/65 (70.8)
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noticeable progression of radiographic damage over 2 yrs of
treatment with TCZ.
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